SNBL USA appoints vp of business development

Mark Crane takes overall responsibility for marketing, sales and business development

SNBL USA, a provider of preclinical services, has announced the arrival of Mark Crane as vice president of business development.

Crane takes responsibility for the company’s marketing, sales and business development efforts. He joins SNBL USA from Ricerca Biosciences where he was vice president of global sales and marketing.

Crane has held similar positions at Bridge Pharmaceutical (formerly GeneLogic), Quest Pharmaceutical Services, and MDS Pharma Services.

SNBL USA is a subsidiary of Shin Nippon Biomedical Laboratories (SNBL), one of the largest CROs in Japan.

You may also like

Research & Development

PPD and SNBL form JV to provide clinical development services in Japan

Will combine PPD's clinical development operations in Japan with SNBL's clinical research division
Regulatory

TurboFil debuts latest generation of through-the-tip benchtop syringe filler

TipFil Plus provides precise, aseptic-ready filling and capping for lab and pharmacy applications
Manufacturing

Concentrating recombinant proteins for drug discovery using centrifugal evaporation

Exploring purification, concentration and sample protection in recombinant protein workflows
Research & Development

COVID-19 immunity lowers the risk of a new pandemic

Researchers at the MRC-University of Glasgow Centre for Virus Research have demonstrated that the likelihood of the emergence of a new SARS-type virus pandemic has been significantly reduced by population-wide immunity to SARS-CoV-2
You need to be a subscriber to read this article.
Click here to find out more.
Research & Development

Cytiva enters research partnership with SRTIGET for next-gen genomic medicine

The pair aim to expand the role of lipid nanoparticle technology into gene therapy delivery, including applications in cancer and inherited blood diseases, CNS delivery for neurological disorders where current methods fail and in vivo stem cell modification that could eliminate toxic conditioning regimens
Research & Development

Shimadzu’s Design Craftech

Fusing traditional Kyoto craft techniques with industrial production
Research & Development

Just – Evotec Biologics wins BARDA contract to optimise antibody biomanufacturing against Ebola and Sudan virus

Just – Evotec Biologics has been selected by BARDA to develop scalable, high-yield manufacturing processes for a monoclonal antibody cocktail targeting filovirus diseases under a multi-year programme valued at up to $10m
Subscribe now